BCHT(SH:688276)2025-02-25 07:55Financial Performance - Total revenue for 2024 was RMB 122,908.41 million, a decrease of 32.64% compared to RMB 182,468.88 million in the previous year[4] - Net profit attributable to shareholders was RMB 23,892.09 million, down 52.31% from RMB 50,100.92 million year-on-year[4] - Basic earnings per share decreased to RMB 0.58, a decline of 52.07% from RMB 1.21 in the previous year[4] Assets and Equity - Total assets increased to RMB 522,359.75 million, reflecting a growth of 3.51% from RMB 504,623.77 million at the beginning of the period[6] - Shareholder equity rose to RMB 422,460.73 million, up 5.08% from RMB 402,036.16 million at the start of the year[6] Market Challenges - The decline in performance was primarily due to reduced public willingness for vaccination and decreased market demand, impacting sales of the herpes zoster vaccine[6] - Significant declines in revenue and profit were attributed to a drop in sales volume of the herpes zoster vaccine[7] Strategic Plans - The company plans to enhance its marketing system and increase public awareness efforts to stimulate user demand[7] - Digital marketing strategies will be optimized to improve market share and enhance core competitiveness[7] Audit and Reporting - The financial data presented is preliminary and subject to change upon final audit in the annual report[9]